FocalTherics (Nasdaq: FOCL) released preliminary unaudited financial results for its HIFU segment for the second quarter of 2026, reporting revenue between $12.7 million and $13.2 million, representing a year-over-year increase of 34% to 39% compared to the same period in 2025.

Gross margin for the quarter came in between 54% and 56%, an increase of 3% to 5% from the second quarter of 2025. The company also reported cash, cash equivalents, and short-term investments from all operations of $21.5 million as of June 30, 2026.

The results reflect only the company's HIFU segment, reported as continuing operations. During the second quarter, FocalTherics classified its Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments as held for sale under applicable accounting standards, designating them as discontinued operations. The company stated the planned exit represents a strategic shift expected to have a significant effect on its operations and financial results.

All figures are preliminary, unaudited, and subject to change as the company prepares its interim condensed consolidated financial statements for the periods ended June 30, 2026 and 2025. FocalTherics stated it does not intend to provide preliminary results in the future.

The company plans to report full second-quarter 2026 financial results after market close on August 13, 2026, followed by a conference call at 4:30 p.m. ET.